Minerva Neurosciences expects roluperidone C19 trial results in second half of next year
NERV•Minerva Neurosciences said its C19 trial of roluperidone remains on track for initial results in the second half of next year. The company presented new analyses supporting the drug’s potential to improve primary negative symptoms and daily functioning in schizophrenia.
1. Trial timeline and prior evidence
Minerva Neurosciences said the ongoing C19 trial remains on track for initial results in the second half of next year. Earlier trials had mixed efficacy results, though both showed improved daily functioning compared with placebo; the FDA declined marketing approval in February 2024, citing insufficient evidence of effectiveness.
2. Potential patient population
The company said the targeted U.S. population is about 900,000 patients, with an estimated market opportunity exceeding $2 billion.




